Bristol-Myers Squibb (NYSE:BMY) Stake Boosted by Nepsis Inc.

Nepsis Inc. lifted its stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 1,143.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 70,768 shares of the biopharmaceutical company's stock after purchasing an additional 65,078 shares during the period. Bristol-Myers Squibb accounts for about 0.9% of Nepsis Inc.'s portfolio, making the stock its 26th largest holding. Nepsis Inc.'s holdings in Bristol-Myers Squibb were worth $3,662,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in the stock. Capital International Investors grew its stake in shares of Bristol-Myers Squibb by 14.1% in the 1st quarter. Capital International Investors now owns 70,203,814 shares of the biopharmaceutical company's stock valued at $3,807,153,000 after buying an additional 8,675,322 shares during the period. M&G Plc acquired a new position in shares of Bristol-Myers Squibb in the 1st quarter valued at $392,608,000. Pzena Investment Management LLC grew its holdings in shares of Bristol-Myers Squibb by 119.8% during the 1st quarter. Pzena Investment Management LLC now owns 12,293,913 shares of the biopharmaceutical company's stock worth $666,699,000 after purchasing an additional 6,701,097 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Bristol-Myers Squibb by 77.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,547,823 shares of the biopharmaceutical company's stock worth $680,469,000 after purchasing an additional 5,461,767 shares during the last quarter. Finally, Van ECK Associates Corp raised its holdings in Bristol-Myers Squibb by 97.2% in the 1st quarter. Van ECK Associates Corp now owns 7,949,173 shares of the biopharmaceutical company's stock valued at $431,084,000 after buying an additional 3,918,234 shares during the period. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

BMY has been the subject of several research analyst reports. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $50.00 target price on shares of Bristol-Myers Squibb in a research note on Friday. Barclays lifted their target price on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an "underweight" rating in a report on Monday, October 7th. Sanford C. Bernstein began coverage on Bristol-Myers Squibb in a research note on Thursday. They set a "market perform" rating and a $56.00 price target on the stock. Deutsche Bank Aktiengesellschaft lowered their target price on Bristol-Myers Squibb from $53.00 to $45.00 and set a "hold" rating for the company in a report on Tuesday, July 23rd. Finally, TD Cowen increased their price target on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a "hold" rating in a research report on Monday, October 7th. Two investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Bristol-Myers Squibb has an average rating of "Hold" and a consensus target price of $53.20.

Bristol-Myers Squibb Trading Up 0.1 %

Shares of BMY stock traded up $0.04 on Friday, reaching $53.22. 7,184,496 shares of the stock were exchanged, compared to its average volume of 14,752,302. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $57.09. The stock has a market cap of $107.88 billion, a P/E ratio of -17.17, a price-to-earnings-growth ratio of 13.75 and a beta of 0.46. The company has a quick ratio of 1.02, a current ratio of 1.16 and a debt-to-equity ratio of 2.86. The firm has a 50 day moving average of $50.36 and a two-hundred day moving average of $46.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. The business had revenue of $12.20 billion during the quarter, compared to the consensus estimate of $11.54 billion. During the same period in the prior year, the firm earned $1.75 earnings per share. The business's quarterly revenue was up 8.7% compared to the same quarter last year. On average, research analysts anticipate that Bristol-Myers Squibb will post 0.77 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Shareholders of record on Friday, October 4th will be paid a $0.60 dividend. The ex-dividend date of this dividend is Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a yield of 4.51%. Bristol-Myers Squibb's payout ratio is currently -77.42%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.